Orforglipron

01

Investigation

What is being claimed?

The Ozempic / Wegovy pill. Same results as the shots. Adherence solved because there is no needle. Milder side effects because it is “just a pill.” First and only oral GLP-1.

People who already know injectable GLP-1s often assume the delivery method is the only thing that changed. Chemistry, ritual, magnitude, and label boundaries all moved.

02

Investigation

What is actually known?

Chemistry and ritual

Orforglipron is a non-peptide small-molecule GLP-1 receptor agonist. Foundayo is a once-daily tablet.

PI-aligned administration: once daily, with or without food; swallow whole (do not break, crush, or chew); one tablet per day. That is the regulatory object. Company materials also contrast it with oral semaglutide’s fasting and limited-water requirements; keep that comparative, not as invented label text.

Labeled strengths: 0.8, 2.5, 5.5, 9, 14.5, and 17.2 mg. Escalation: start 0.8 mg → after ≥30 days, 2.5 mg → after ≥30 days, 5.5 mg → then may step to 9, 14.5, and 17.2 mg after ≥30 days at each level, by response and tolerability. Maximum 17.2 mg once daily.

Capsule → tablet map (older ATTAIN papers often use capsule mg): 1→0.8, 3→2.5, 6→5.5, 12→9, 24→14.5, 36→17.2. So ATTAIN arms reported as 6 / 12 / 36 mg capsules correspond to 5.5 / 9 / 17.2 mg tablets. Prefer labeled tablet names after that explanation.

CYP3A4 (PI): maximum 9 mg once daily with a strong CYP3A4 inhibitor; avoid strong CYP3A4 inhibitors that also inhibit OATP1B; avoid strong CYP3A4 inducers; with moderate inducers, monitor effectiveness and escalate as needed.

ATTAIN-1 (no diabetes)

Published in NEJM (2025). About 3,100 adults. At 72 weeks, treatment-regimen mean weight reductions on the order of 7–11% across studied doses versus about 2% placebo, largest at the top dose (~11.2%). GI events class-familiar. Discontinuations for adverse events higher than placebo.

ATTAIN-2 (type 2 diabetes + overweight/obesity)

Published in The Lancet (2025). Mean weight reductions smaller than ATTAIN-1 at matched dose levels (top dose on the order of ~9.6% vs ~2.5% placebo under the treatment-regimen estimand), with glycemic improvement.

ACHIEVE and oral comparison

Diabetes Phase 3 includes a head-to-head versus oral semaglutide (ACHIEVE-3, The Lancet): orforglipron showed greater A1c and weight reductions in reported analyses, with more GI burden and discontinuations in that comparison. Useful for oral-versus-oral tradeoffs. Not a substitute for a diabetes label.

Regulatory

Foundayo approved April 1, 2026 for chronic weight management with diet and activity. Diabetes indication pending as of July 2026.

03

Investigation

What remains uncertain?

• How often “wanted a pill” survives escalation GI in real clinics
• How Foundayo competes with oral semaglutide products that still require fasting rules
• Insurance and cash-pay durability after launch novelty fades
• Lean-mass / living-well protocols under daily oral GLP-1
• Diabetes labeling timing and final diabetes dosing story
• Orforglipron-specific long-term CV outcomes

04

Investigation

Why should an RD care?

Object literacy. Foundayo is orforglipron: oral non-peptide GLP-1. Not liquid Ozempic in a capsule, not compounded “oral sema,” not interchangeable with Rybelsus by brand folklore.

Ritual literacy. Prior failure on oral semaglutide because of empty-stomach / limited-water rules may not transfer. Expecting zero GI because “pills are gentle” will. Foundayo’s PI object is simpler: once daily, with or without food.

Expectation literacy. ATTAIN averages are meaningful and usually quieter than dual-agonist injection marketing. Match goals to the product, not a headline from a different molecule.

Label boundary. Weight-management conversations can reference an approved product. Diabetes-only use still waits on indication and PI.

Same living-well work. Protein, resistance training, GI pacing, shame detox, maintenance thinking. Delivery form does not retire nutrition care.

Usable line: “Foundayo is a daily GLP-1 tablet. It’s a small molecule, not a peptide shot. The label says take it once a day with or without food; it doesn’t use the fasting and limited-water rules that oral semaglutide needs. Phase 3 trials showed meaningful weight loss, usually less on average than the strongest injectable dual agonists. It’s approved for weight management; a diabetes indication isn’t approved yet.”